The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.
Mona Lisa Alattar
No relevant relationships to disclose
Hagop Kantarjian
No relevant relationships to disclose
Jan Andreas Burger
No relevant relationships to disclose
Mary Ann Richie
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Marina Konopleva
No relevant relationships to disclose
Stefan Faderl
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Naval Guastad Daver
No relevant relationships to disclose
Tapan M. Kadia
No relevant relationships to disclose
Jorge E. Cortes
Research Funding - Celgene
Farhad Ravandi
Consultant or Advisory Role - Bayer/Onyx (U)
Honoraria - Bayer/Onyx; Celgene
Research Funding - Bayer/Onyx; Celgene